NeuroPace, Inc. (NPCE): Price and Financial Metrics
NPCE Price/Volume Stats
| Current price | $13.32 | 52-week high | $18.15 |
| Prev. close | $13.56 | 52-week low | $3.80 |
| Day low | $13.04 | Volume | 13,056 |
| Day high | $13.49 | Avg. volume | 105,207 |
| 50-day MA | $14.36 | Dividend yield | N/A |
| 200-day MA | $9.90 | Market Cap | 382.55M |
NPCE Stock Price Chart Interactive Chart >
NeuroPace, Inc. (NPCE) Company Bio
NeuroPace, Inc. operates as a medical device company in the United States. The company develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. Its RNS system also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Latest NPCE News From Around the Web
Below are the latest news stories about NEUROPACE INC that investors may wish to consider to help them evaluate NPCE as an investment opportunity.
NeuroPace Announces Early Completion of Patient Enrollment in NAUTILUS Pivotal StudyNAUTILUS is the first and only pivotal clinical study to evaluate neuromodulation therapy for treating drug refractory idiopathic generalized epilepsy Neuromodulation therapy is not currently indicated for patients with drug refractory generalized epilepsy If successful, NeuroPace’s RNS System would represent the first neuromodulation indication in idiopathic generalized epilepsy MOUNTAIN VIEW, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial, growth-stage, |
NeuroPace to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceMOUNTAIN VIEW, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the 42nd Annual J.P. Morgan Healthcare Conference at 7:30am PT (10:30am ET) on Thursday, January 11, 2024, in San Francisco, CA as well as host investor meetings prior to and during the conference.The presentation will be accessible via live webc |
NeuroPace to Leverage the Power of its RNS System’s Novel Data Collection, Brain Monitoring and Analysis Capabilities in Groundbreaking CollaborationFirst of its kind, multi-year collaboration leverages RNS System’s data to track responses of implanted RNS System patients enrolled in a biotechnology company’s clinical trial In strategic data collaboration, clinical-stage biotechnology company to pay NeuroPace up to $3.7 million over two years to gain non-exclusive access to NeuroPace’s proprietary biomarker monitoring and data analysis capabilities for trial patients MOUNTAIN VIEW, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (N |
NeuroPace and the RNS System Showcased at the 77th American Epilepsy Society (AES) Annual MeetingRNS System featured in over 50 Scientific Presentations and PostersMOUNTAIN VIEW, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced that the Company will have a substantial presence at the 77th American Epilepsy Society Annual Meeting (AES 2023), to be held in Orlando, Florida and virtually from December 1-5, 2023. “The Society’s annual meeting is th |
NeuroPace to Present at the Piper Sandler 35th Annual Healthcare ConferenceMOUNTAIN VIEW, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced will present at the Piper Sandler 35th Annual Healthcare Conference, taking place November 28-30 in New York, NY. Joel Becker, NeuroPace’s Chief Executive Officer, will provide a corporate presentation on Tuesday, November 28 at 2:30pm ET, and management will participate in one-on-one m |
NPCE Price Returns
| 1-mo | -0.08% |
| 3-mo | -8.58% |
| 6-mo | 112.78% |
| 1-year | 196.66% |
| 3-year | -49.16% |
| 5-year | N/A |
| YTD | 29.19% |
| 2023 | 591.95% |
| 2022 | -85.22% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...